We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 21 juli 2017

Nature Reviews Clinical Oncology - Table of Contents alert Volume 14 Issue 8

If you are unable to see the message below, click here to view.

Nature Reviews Clinical Oncology

Searching for immunotherapy answers?

Illuminate immunotherapy treatment opportunities from the complex immuno regulation pathways with Caris Molecular Intelligence®. We provide oncologists reliable molecular information to inform immunotherapy treatment decisions using validated assays for MSI, TML and PD-L1 testing in our state-of-the-art laboratory.

Learn more.
August 2017 Volume 14 Number 8Advertisement
Nature Reviews Clinical Oncology cover
2016 2-year Impact Factor 20.693 Journal Metrics 2-year Median 12
In this issue
Research Highlights
News and Views

Also this month
 Featured article:
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas & Georgina V. Long

The National Cancer Research Institute (NCRI) Cancer Conference is the largest annual cancer research conference in the UK, featuring ground-breaking research. The Conference brings together people at all career levels and is the ideal setting to discuss ideas and establish new collaborations with colleagues from around the world. Informative and interactive sessions cover the breadth of cancer research and we hope you will join us at this important meeting.

Recommend to library
A community map of cancer immunity

Immunotherapy is influenced by a complex set of tumour, host and environmental factors. Such factors combine to characterise the immunological status — or cancer-immune set point — of an individual.

Collaborate with peers to update, evolve and improve the cancer-immune set point framework
A supplement to Nature Biotechnology | Nature Medicine | Nature Reviews Drug Discovery

Medtech Dealmakers explores the dealmaking strategies of the growing medical technology industry, and provides in-depth analysis of emerging technologies, as well as showcase innovative companies seeking partners. Check out the latest issue for medtech dealmaking and financing trends in 2016, and diagnostics deals from the past year- particularly for immuno oncology applications.

Download the issue for FREE
WIN to avoid the valley of death
Published online: 20 July 2017
p453 | doi:10.1038/nrclinonc.2017.113

Full Text | PDF

Scientific advice — is drug repurposing missing a trick?
Pan Pantziarka
Published online: 23 May 2017
p455 | doi:10.1038/nrclinonc.2017.69

Scientific Advice meetings are a mechanism to improve communications between drug developers and regulators during the drug-development process. While standard practice for industry, the benefits provided by these meetings are under-utilised by academia. In the context of drug repurposing, can scientific advice, as part of a proposed new R&D tax credits scheme, help to unblock some of the obstacles in the way to clinical adoption?

Full Text | PDF


Targeted therapies: Defining the best-in-class in NSCLC
Published online: 27 June 2017
p457 | doi:10.1038/nrclinonc.2017.99


Lung Cancer: Frontline nivolumab — CheckMate 026 ends in stalemate
Published online: 20 July 2017
p458 | doi:10.1038/nrclinonc.2017.102


Targeted therapies: Lenvatinib SELECTs survival benefit
Published online: 11 July 2017
p458 | doi:10.1038/nrclinonc.2017.103


Immunotherapy: PD-1 blockade exploiting MMR deficiency
Published online: 27 June 2017
p459 | doi:10.1038/nrclinonc.2017.98


Haematological cancer: Feasible mutation-targeted therapy
Published online: 11 July 2017
p460 | doi:10.1038/nrclinonc.2017.108


Breast cancer: Olaparib improves PFS
Published online: 20 June 2017
p460 | doi:10.1038/nrclinonc.2017.93


Haematological cancer: Brentuximab vedotin — a new standard for cutaneous T-cell lymphoma
Published online: 20 June 2017
p460 | doi:10.1038/nrclinonc.2017.94



Breast cancer: Microenvironment mediates differential resistance | Immunotherapy: Neuropilin-1 is required for Treg stability | Haematological cancer: Genomic disruption of CD7 avoids fractricide

Nature Reviews Clinical Oncology
JOBS of the week
Drug discovery project leaders
Research Fellow: Neuroscience of Pain, Analgesics, AAV Gene Therapy Job
Mayo Clinic
Institute Associate Scientist II – Mouse Modeling - Microinjectionist
MD Anderson Cancer Center
Postdoctorial Fellowship - Department of Tumor Biology, Institute for Cancer Research
Oslo University Hospital
More Science jobs from
Nature Reviews Clinical Oncology
The 2nd International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2018)
Berlin, Germany
More science events from
Haematological cancer: Where are we now with the treatment of multiple myeloma?
Gareth J. Morgan & Leo Rasche
Published online: 13 June 2017
p461 | doi:10.1038/nrclinonc.2017.82
The current standard-of-care therapy for patients with multiple myeloma is autologous stem-cell transplantation; however, whether this approach should be enhanced or displaced by triplet combination therapy is the subject of ongoing debate. We discuss the latest trial that has attempted to address this question and the impact of transplantation and triplet therapy assessment and surrogate end points in future trial design.
Full Text | PDF

Leukemia: Collection on Acute Myeloid Leukemia

AML is an area of focus for Leukemia and this collection brings together a number of recent key articles published in the journal. 

Access this collection free online for six months

Funded by a grant from Astex Pharmaceuticals, Inc.
(a member of the Otsuka group)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke, Keith T. Flaherty, Antoni Ribas & Georgina V. Long
Published online: 04 April 2017
p463 | doi:10.1038/nrclinonc.2017.43
In less than a decade, the treatment landscape of metastatic melanoma has changed dramatically. Novel targeted agents and immunotherapies are revolutionizing patient outcomes, but the range of available drugs complicates clinical decision-making. Herein, the authors chart the therapeutic advances and review the current evidence that can be used to guide therapeutic decisions for individual patients with metastatic melanoma, highlighting knowledge gaps.
Abstract | Full Text | PDF

Charged-particle therapy in cancer: clinical uses and future perspectives
Marco Durante, Roberto Orecchia & Jay S. Loeffler
Published online: 14 March 2017
p483 | doi:10.1038/nrclinonc.2017.30
Conventional radiotherapy with X-rays is being replaced by radiotherapy with high-energy charged particles, an approach that better spares healthy tissue from radiation but is associated with higher costs. Evidence supporting the cost-effectiveness of either modality can only come from the results of randomized clinical trials. The authors of this Review discuss ongoing randomized trials of charged-particle therapies as well as aspects related to radiobiology, which need to be taken into account in order to fully exploit the therapeutic potential of charged particles.
Abstract | Full Text | PDF

The NCRI Cancer Conference is the UK's largest cancer research meeting, bringing together a unique mix of people at all career levels to network, discuss ideas and establish new collaborations. Informative and interactive sessions cover the breadth of cancer research and we hope you will join us at this important meeting.
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
Lucas Moreno et al.
Published online: 16 May 2017
p497 | doi:10.1038/nrclinonc.2017.59
Precision medicine has dramatically changed the landscape of drug development in oncology, but this paradigm shift remains to be adopted in early phase clinical trials of molecularly targeted agents and immunotherapeutic agents in children with cancer. The authors, members of the Innovative Therapies for Children with Cancer (ITCC) Consortium, describe trial design strategies to enable drugs with promising activity to progress rapidly to randomized studies and, therefore, substantially accelerate drug development for children and adolescents with cancer.
Abstract | Full Text | PDF | Supplementary information

The need for multidisciplinarity in specialist training to optimize future patient care
Alison C. Tree et al.
Published online: 29 November 2016
p508 | doi:10.1038/nrclinonc.2016.185
A multidisciplinary approach is essential for the optimization of patient care in oncology, especially in the current landscape, in which standard-of-care approaches to cancer treatment are evolving towards highly targeted treatments, precise image guidance and personalized cancer therapy. Herein, the authors discuss current career development pathways for oncologists, suggesting strategies to improve clinical training and research, with specific emphasis on the involvement of trainees in multidisciplinary teams.
Abstract | Full Text | PDF

Open for Submissions

npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine.

The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.

Explore the benefits of submitting your manuscript.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature